Peters Glenn, Kulbersh Brian, Mantle Belinda, Bell Walter, Grizzle William, Rosenthal Eben
Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, AL 35294-0012, USA.
Laryngoscope. 2007 Dec;117(12):2163-8. doi: 10.1097/MLG.0b013e318149241f.
Sestamibi scans for localization of abnormal parathyroid glands in patients with hyperparathyroidism are widely used at many institutions. Minimally invasive parathyroid surgery demands accurate preoperative localization imaging; however, nonlocalizing sestamibi scans occur in 15% of patients with primary hyperparathyroidism. It remains unknown why some sestamibi scans fail to localize. We hypothesize that an increase in microvascular density (MVD) within an adenoma will result in rapid tracer washout and a subsequent nonlocalizing scan. This study investigates the role of MVD in sestamibi localization.
Retrospective chart review with immunohistochemical staining and data analysis.
Medical records of 83 patients who had a sestamibi scan for evaluation of primary hyperparathyroidism and underwent initial parathyroidectomy from 2000 to 2002 were retrospectively reviewed. Patients' age, sex, preoperative imaging results, operative procedure, gland weight, and histologic findings were collected. Immunohistochemistry was performed to assess MVD.
Of the 75 preoperative sestamibi scans used, 51 patients had a localizing scan, and 24 were nonlocalizing. Localizing sestamibi scans for primary hyperparathyroidism demonstrated a sensitivity of 94% and specificity of 85%. By identifying multiglandular hyperplasia, nonlocalizing sestamibi scans produced a sensitivity of 83%. The localizing group had a greater percentage of solitary adenomas (94%) compared with the nonlocalizing group (15.6%) (P < .001). The mean gland weight for the nonlocalizing group was less than 398 g compared with the localizing groupweight of 1,113 g (P < .001). The mean MVD for localizing scan group was 229 vessels per high-power field,and the mean for the nonlocalizing scans was 213 vessels per high-power field (P = .2).
MVD does not predict whether sestamibi scans are localizing or nonlocalizing.
在许多机构中,锝-99m甲氧基异丁基异腈(MIBI)扫描用于定位甲状旁腺功能亢进患者异常甲状旁腺的情况广泛应用。微创甲状旁腺手术需要准确的术前定位成像;然而,15%的原发性甲状旁腺功能亢进患者会出现MIBI扫描未能定位的情况。目前尚不清楚为何有些MIBI扫描无法定位。我们推测腺瘤内微血管密度(MVD)增加会导致示踪剂快速洗脱,进而导致扫描未能定位。本研究调查MVD在MIBI定位中的作用。
采用免疫组织化学染色和数据分析进行回顾性病历审查。
回顾性分析2000年至2002年期间83例因评估原发性甲状旁腺功能亢进而行MIBI扫描并接受初次甲状旁腺切除术患者的病历。收集患者的年龄、性别、术前影像学结果、手术方式、腺体重量和组织学检查结果。进行免疫组织化学以评估MVD。
在使用的75次术前MIBI扫描中,51例患者扫描定位,24例未定位。原发性甲状旁腺功能亢进的定位MIBI扫描显示敏感性为94%,特异性为85%。通过识别多腺体增生,未定位的MIBI扫描敏感性为83%。与未定位组(15.6%)相比,定位组中孤立性腺瘤的比例更高(94%)(P <.001)。未定位组的平均腺体重量小于398 g,而定位组为1113 g(P <.001)。定位扫描组的平均MVD为每高倍视野229个血管,未定位扫描组的平均MVD为每高倍视野213个血管(P =.2)。
MVD无法预测MIBI扫描是否能定位。